These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 20098287)

  • 1. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma.
    Vivarelli M; Dazzi A; Zanello M; Cucchetti A; Cescon M; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
    Transplantation; 2010 Jan; 89(2):227-31. PubMed ID: 20098287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
    Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
    Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria.
    Zhou J; Wang Z; Wu ZQ; Qiu SJ; Yu Y; Huang XW; Tang ZY; Fan J
    Transplant Proc; 2008 Dec; 40(10):3548-53. PubMed ID: 19100435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression.
    Vivarelli M; Cucchetti A; Piscaglia F; La Barba G; Bolondi L; Cavallari A; Pinna AD
    Liver Transpl; 2005 May; 11(5):497-503. PubMed ID: 15838913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
    Toso C; Meeberg GA; Bigam DL; Oberholzer J; Shapiro AM; Gutfreund K; Ma MM; Mason AL; Wong WW; Bain VG; Kneteman NM
    Transplantation; 2007 May; 83(9):1162-8. PubMed ID: 17496530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.
    Kneteman NM; Oberholzer J; Al Saghier M; Meeberg GA; Blitz M; Ma MM; Wong WW; Gutfreund K; Mason AL; Jewell LD; Shapiro AM; Bain VG; Bigam DL
    Liver Transpl; 2004 Oct; 10(10):1301-11. PubMed ID: 15376305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indications and management of everolimus after liver transplantation.
    Bilbao I; Sapisochin G; Dopazo C; Lazaro JL; Pou L; Castells L; Caralt M; Blanco L; Gantxegi A; Margarit C; Charco R
    Transplant Proc; 2009; 41(6):2172-6. PubMed ID: 19715864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of an immunosuppressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence.
    Castroagudín JF; Molina E; Tomé S; Otero E; Rodríguez M; Varo E
    Transplant Proc; 2009 Apr; 41(3):1003-4. PubMed ID: 19376410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C?
    Moya A; Berenguer M; Aguilera V; Juan FS; Nicolás D; Pastor M; López-Andujar R; Rayón M; Orbis F; Mora J; De Juan M; Carrasco D; Vila JJ; Prieto M; Berenguer J; Mir J
    Liver Transpl; 2002 Nov; 8(11):1020-7. PubMed ID: 12424715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus in liver transplant recipients: a large single-center experience.
    Vivarelli M; Dazzi A; Cucchetti A; Gasbarrini A; Zanello M; Di Gioia P; Bianchi G; Tamè MR; Gaudio MD; Ravaioli M; Cescon M; Grazi GL; Pinna AD
    Transplant Proc; 2010 Sep; 42(7):2579-84. PubMed ID: 20832548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for fatal recurrence of hepatocellular carcinoma and their role in selecting candidates for liver transplantation.
    Zou WL; Zang YJ; Chen XG; Shen ZY
    Hepatobiliary Pancreat Dis Int; 2008 Apr; 7(2):145-51. PubMed ID: 18397848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orthotopic liver transplantation for hepatocellular carcinoma: a thirteen-year single-center experience.
    Castroagudín JF; Molina E; Bustamante M; Tomé S; Otero E; Martínez J; Segade FR; Conde R; Varo E
    Transplant Proc; 2008 Nov; 40(9):2975-7. PubMed ID: 19010164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver transplantation and tacrolimus monotherapy for hepatocellular carcinoma with expanded criteria.
    Dalgic A; Karakayali H; Moray G; Emiroglu R; Sozen H; Torgay A; Haberal M
    Transplant Proc; 2005 Sep; 37(7):3154-6. PubMed ID: 16213334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis.
    Bozorgzadeh A; Orloff M; Abt P; Tsoulfas G; Younan D; Kashyap R; Jain A; Mantry P; Maliakkal B; Khorana A; Schwartz S
    Liver Transpl; 2007 Jun; 13(6):807-13. PubMed ID: 17539001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver transplantation results for hepatocellular carcinoma in Chile.
    Gabrielli M; Vivanco M; Hepp J; Martínez J; Pérez R; Guerra J; Arrese M; Figueroa E; Soza A; Yáñes R; Humeres R; Rios H; Palacios JM; Zapata R; Sanhueza E; Contreras J; Rencoret G; Rossi R; Jarufe N
    Transplant Proc; 2010; 42(1):299-301. PubMed ID: 20172336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus therapy in liver transplant patients: an initial experience at a single center.
    Nocera A; Andorno E; Tagliamacco A; Morelli N; Bottino G; Ravazzoni F; Casaccia M; Barocci S; Alice S; Santori G; Ghirelli R; Valente U
    Transplant Proc; 2008; 40(6):1950-2. PubMed ID: 18675098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation.
    Saab S; Yeganeh M; Nguyen K; Durazo F; Han S; Yersiz H; Farmer DG; Goldstein LI; Tong MJ; Busuttil RW
    Liver Transpl; 2009 Nov; 15(11):1525-34. PubMed ID: 19877207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C.
    Shimoda M; Ghobrial RM; Carmody IC; Anselmo DM; Farmer DG; Yersiz H; Chen P; Dawson S; Durazo F; Han S; Goldstein LI; Saab S; Hiatt J; Busuttil RW
    Liver Transpl; 2004 Dec; 10(12):1478-86. PubMed ID: 15558585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis.
    Liang W; Wang D; Ling X; Kao AA; Kong Y; Shang Y; Guo Z; He X
    Liver Transpl; 2012 Jan; 18(1):62-9. PubMed ID: 21964956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical results in patients with dual hepatitis B- and C-related hepatocellular carcinoma compared with hepatitis B- or C-related hepatocellular carcinoma.
    Chen MF; Jeng LB; Lee WC; Chen TC
    Surgery; 1998 May; 123(5):554-9. PubMed ID: 9591008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.